Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03731442 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03731442 · ClinicalTrials.gov record · last posted 2018-12-12

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

StatusRecruiting
PhasePhase 3
Started2018-11-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 12, 2018 (before its estimated October 31, 2022 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2018-11-05; most recent amendment 2018-12-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT03731442
Lead Sponsor Chinese Academy of Medical Sciences
Collaborators: The First Affiliated Hospital with Nanjing Medical University, Tianjin Medical University Cancer Institute and Hospital, Anyang Tumor Hospital, Fujian Cancer Hospital, Peking University Cancer Hospital & Institute, Hebei Medical University Fourth Hospital
Conditions Esophageal Cancer
Enrollment 300 participants
Start Date 2018-11-01
Primary Completion 2022-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2018-12-12